Sandoz’ Saynor Insists US Biosimilars Market Is Stepping Up
US And Europe Were Once ‘Venus And Mars’ – But Promising Signs Emerging
Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.
You may also be interested in...
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”
A wave of recent biosimilar launches in the US has provided multi-source competition on several major brands and stands to boost the country’s biosimilars market, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen.